Why weight-loss drugs won’t be banned in 2027 — WADA

Femi Akinyemi

Athletes will not be banned from using weight-loss drugs under the World Anti-Doping Agency’s (WADA) rules for 2027, but the substances will remain on its monitoring list.

WADA confirmed the decision following a meeting of its executive committee as it continues to assess whether the drugs, known as GLP-1 receptor agonists, can enhance performance and pose a risk of abuse in sport.

The 2027 Prohibited List will take effect in January and will be reviewed annually.

Medications such as Ozempic and Mounjaro have become increasingly common outside elite sport, with several high-profile figures publicly discussing their use.

Among them is 23-time Grand Slam champion Serena Williams, who revealed last year, while on a break from professional tennis, that she had been using weight-loss medication.

WADA’s senior director for science and medicine, Professor Olivier Rabin, however, warned athletes against using the drugs without medical supervision.

“It’s such a drastic change in your physiology that it can come with serious side effects and risks, in particular for athletes,” he told BBC Sport.

Why have the drugs not been banned?

Semaglutide, marketed under brands including Ozempic and Wegovy, was first placed on WADA’s monitoring list in 2024.

Tirzepatide, commonly marketed as Mounjaro, was added to the list this year.

ALSO READ: FULL LIST: Premier League announces festive fixtures

For a substance to be moved from the monitoring list to the prohibited list, it must meet at least two of three criteria: the potential to enhance sporting performance, a health risk to athletes, or a violation of the spirit of sport.

WADA has started one study and is preparing another to examine the effects of the drugs under conditions designed to mimic high-level exercise.

Rabin said the research would take time because the studies are being conducted under controlled conditions.

“What we want to see is whether some of the pharmacological impact on human physiology that has been observed in obese patients would also occur in non-obese, highly trained people,” he said.

He added that any potential benefits could be offset by side effects including nausea, fatigue and loss of muscle mass.

“If you’re an athlete and you lose muscle mass, that may be very counterproductive for what you’re trying to achieve,” Rabin said.

“So all these elements show you that it’s not a very straightforward answer.”

Under the usual timetable, any change approved at WADA’s executive committee meeting next September would take effect in January 2028.

Which sports could be at risk?

Weight-loss drugs could be particularly attractive to athletes in sports where body weight is closely linked to performance.

These include weight-category sports such as boxing and wrestling, as well as horse racing, where jockeys must meet strict weight requirements before races.

“A lot of sports would benefit from weight control and weight management,” Rabin said.

“Not only those in weight-category sports, but all sorts of sports.”

He also identified long-distance runners and cyclists as athletes for whom weight control can be an important consideration.

“There are sports as well where aesthetics play a role,” he said. “It can be gymnastics, can be horse riding, can be many different sports where you don’t have weight categories, but physical appearance is quite important.”

Athletes’ use of weight-loss drugs

Very few athletes have publicly acknowledged using weight-loss drugs.

The most prominent case is Williams, who said she had struggled to lose weight after having children.

Williams is also a spokesperson for Ro, a company that sells GLP-1 medications and in which her husband is an investor.

A recent Loughborough University study that surveyed more than 100 sports medicine physicians worldwide found that 12% were aware of athletes using GLP-1 drugs despite having no medical need for them.

For now, WADA will continue monitoring the substances while research into their effects on athletes progresses.

[ruby_related total=5 layout=5]